Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D G Shand

Showing results (11-20 of 153) with videos related to

Pageof 16
Sort By:
The Medical Clinics of North America|September 1, 1974
Individualization of propranolol therapyD G Shand
Gerontology|January 1, 1982
Biological determinants of altered pharmacokinetics in the elderlyD G Shand
Postgraduate Medical Journal|January 1, 1976
Pharmacokinetics of propranolol: a reviewD G Shand
Circulation|June 1, 1983
How should the proper dose of a beta blocker be determined?D G Shand
Acta Pharmaceutica Suecica|December 1, 1975
Proceedings: Presystemic hepatic eliminationG R Wilkinson, D G Shand
Rational Drug Therapy|December 1, 1979
The present status of propranololP A Routledge, D G Shand
Clinical Pharmacokinetics|January 1, 1976
Propranolol disposition in chronic liver disease: a physiological approachR A Branch, D G Shand
Southern Medical Journal|May 1, 1978
Propranolol in the treatment of cardiovascular diseaseA J Wood, D G Shand
Biochemical Pharmacology|July 1, 1971
Metabolism of propranolol by rat liver microsomes and its inhibition by phenothiazine and tricyclic antidepressant drugsD G Shand, J A Oates
Clinical Pharmacology and Therapeutics|July 1, 1973
Disposition of propranolol. VI. Independent variation in steady-state circulating drug concentrations and half-life as a result of plasma drug binding in manG H Evans, D G Shand
Pageof 16

Showing results (11-20 of 153) with videos related to

Sort By:
Pageof 16
The Medical Clinics of North America|September 1, 1974
Individualization of propranolol therapyD G Shand
Gerontology|January 1, 1982
Biological determinants of altered pharmacokinetics in the elderlyD G Shand
Postgraduate Medical Journal|January 1, 1976
Pharmacokinetics of propranolol: a reviewD G Shand
Circulation|June 1, 1983
How should the proper dose of a beta blocker be determined?D G Shand
Acta Pharmaceutica Suecica|December 1, 1975
Proceedings: Presystemic hepatic eliminationG R Wilkinson, D G Shand
Rational Drug Therapy|December 1, 1979
The present status of propranololP A Routledge, D G Shand
Clinical Pharmacokinetics|January 1, 1976
Propranolol disposition in chronic liver disease: a physiological approachR A Branch, D G Shand
Southern Medical Journal|May 1, 1978
Propranolol in the treatment of cardiovascular diseaseA J Wood, D G Shand
Biochemical Pharmacology|July 1, 1971
Metabolism of propranolol by rat liver microsomes and its inhibition by phenothiazine and tricyclic antidepressant drugsD G Shand, J A Oates
Clinical Pharmacology and Therapeutics|July 1, 1973
Disposition of propranolol. VI. Independent variation in steady-state circulating drug concentrations and half-life as a result of plasma drug binding in manG H Evans, D G Shand
Pageof 16